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Introduction: Pegloticase, a PEGylated recombinant porcine uricase, is approved for treating refractory gout at a
dose of 8 mg intravenous (IV) every 2 weeks. However, during phase 1 testing, pharmacokinetics supported less
frequent dosing. Also, single doses of pegloticase unexpectedly induced antibodies (Ab) that bound to
polyethylene glycol (PEG). We have conducted a phase 2 trial to evaluate every 3-week dosing, and to further
define the Ab response to pegloticase. Organ transplant recipients were included, as they are prone to severe
gout that is difficult to manage, and because treatment to prevent graft rejection might influence the immune
response to pegloticase.
Methods: Plasma uricase activity (pUox), urate concentration (pUA), and clinical response were monitored during
up to 5 infusions in 30 patients, including 7 organ transplant recipients. Depending on whether pUA <6 mg/dL
was achieved and maintained, patients were classified as non (NR), persistent (PR), or transient (TR) responders.
Ab to pegloticase and 10 kDa mPEG were monitored by enzyme linked immunosorbent assay and specificity
was further defined.
Results: We observed 17 PR, 12 TR, and 1 NR; 21 patients (16 PR, 5 TR) received all 5 infusions. Over the 15-week
trial, pUA in PR averaged 1.0 ± 0.4 mg/dL; T½ for pUox was approximately 13 days, and area under the curve after
dose 5 was approximately 30% higher than after dose 1. PR showed clinical benefit and in some, tophi resolved.
In 11 of 12 TR, pUox fell rapidly and hyperuricemia recurred before dose 2. In all TR and NR, loss of response to
pegloticase was accompanied by Ab to PEG, which was pre-existing in half of those who had no prior exposure
to pegloticase. No PR, and 1 one out of 7 organ transplant recipients, had a sustained Ab response to
pegloticase.
Conclusions: Every 3-week dosing is effective and may enhance the utility of pegloticase for treating refractory
gout. Ab to PEG, which were pre-existing or induced by treatment, caused rapid loss of efficacy and increased the
risk of infusion reactions. Organ transplant recipients can benefit from pegloticase, and may be less prone than
non-recipients to developing anti-PEG Ab. Investigation of immunosuppressive strategies to minimize anti-PEG
Ab is warranted.
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Owing to poorly controlled hyperuricemia, a subset of
gout patients reach an advanced stage, typically charac-
terized by debilitating arthropathy and tophi [1-3]. At
this late stage, relieving arthritis and eliminating tophi
are difficult to achieve, and treatment is often compli-
cated by age- and gout-associated comorbidities, such as
hypertension, renal insufficiency, diabetes and vascular
disease. In 2010, pegloticase (Krystexxa®), a PEGylated
recombinant porcine urate oxidase, was approved as an
Orphan Drug specifically for treating refractory gout.
The FDA-approved dose of pegloticase, 8 mg i.v. every
3 weeks, was more effective in maintaining pUA below
6 mg/dL than every four week dosing in phase 3 trials
[4,5]. Whether every two week dosing is necessary to
meet that target is unclear, as in phase 1 testing, a single
infusion of 8 mg maintained pUA at <2 mg/dL for
21 days, although this dose was tested in only four pa-
tients [6]. We have conducted the present trial to assess
the urate-lowering efficacy of an 8 mg dose of peglo-
ticase infused at three-week intervals. The difference
between a two- and a three-week infusion schedule is
not trivial, considering that travel to spend most of a day
in an infusion clinic is often difficult for patients with
advanced gout.
In addition to the optimal infusion schedule, we have
investigated two other issues relevant to the utility and
safety of pegloticase. One is a hypothetical concern: that
pegloticase might exacerbate oxidative stress by deplet-
ing uric acid while generating hydrogen peroxide. We
have reported separately that oxidative stress status did
not worsen in patients during the present trial, as eryth-
rocytes had more than sufficient enzymatic capacity to
eliminate the hydrogen peroxide generated from urate
oxidation, and to compensate for the loss of urate in
maintaining the antioxidant capacity of blood [7].
The second focus of this report is the humoral im-
mune response to pegloticase. During phase 1 testing we
found that single doses of pegloticase induced Ab that
appeared to recognize PEG [6,8]. This was unexpected,
as PEGylation of biologic agents is intended in part to
reduce immunogenicity, and PEG itself is not immuno-
genic [9]. In phase 3 trials, high titer Ab to pegloticase
was the principle reason for loss of efficacy, but epitope
specificity was not reported [4]. The existence and sig-
nificance of Ab to PEG in humans is controversial, but
of potential importance as PEGylated biologics are used
to treat a variety of diseases, including some of interest
to rheumatologists [10,11].
The present trial was designed to establish whether
anti-PEG Ab is a transient or persistent immune response
to pegloticase during repeated dosing over a period
sufficient to achieve clinical benefit. We have explored
in detail the relationship between Ab evolution and thepharmacokinetics and pharmacodynamics associated with
pegloticase therapy, as well as the effect on tolerability. In
part to expand clinical experience with pegloticase, we in-
cluded among the 30 trial participants seven organ trans-
plant recipients, a patient category at high risk for severe
gout that was excluded from previous clinical trials [12].
As these patients require chronic immunosuppression to
prevent organ graft rejection, we were interested in evalu-
ating their susceptibility to developing Ab to pegloticase.
Methods
Materials
Pegloticase and 10 kDa mPEG (10 kDa p-nitrophenylcarbo-
nate-activated monomethoxyPEG) were provided by Savient
Pharmaceuticals (Bridgewater, NJ, USA). PEG-diol was ob-
tained from Sigma-Aldrich (St. Louis, MO, USA), and PEGy-
lated bovine adenosine deaminase (PEG-ADA) from Enzon
Pharmaceuticals, Inc. (Piscataway, NJ, USA). Pegloticase was
used under Investigator IND no. 11274 held by JSS.
Study design
An open label trial was conducted at Duke University
Medical Center to evaluate the ability of pegloticase
infused every three weeks to maintain pUA below 6 mg/dL
in 30 patients with refractory, symptomatic gout who
were ≥18 years old and had serum uric acid concentra-
tion >7 mg/dL. Inclusion and exclusion criteria were
similar to those in other trials of pegloticase [4,6,8,13], ex-
cept for the participation of seven organ transplant recipi-
ents who were receiving immunosuppressive therapy to
prevent graft rejection, and three patients who had re-
ceived pegloticase in previous phase 1 or phase 2 trials
>1 year prior to the present study. The trial protocol was
approved by the Duke University Institutional Review
Board, and all patients gave written informed consent.
The protocol called for five infusions of pegloticase
(8 mg) at three-week intervals. Other urate-lowering
therapy was discontinued 14 days prior to the trial. Un-
less contraindicated, colchicine or a non-steroidal anti-
inflammatory drug was given as prophylaxis against gout
flares. To minimize infusion reactions, patients received
prednisone (20 mg) and fexofenadine (60 mg) orally the
evening before each pegloticase infusion. Fexofenadine
was repeated on the morning of the infusion, along with
200 mg of intravenous (i.v.) hydrocortisone.
Pharmacokinetic and pharmacodynamic measurements
Pegloticase concentration in plasma (pUox) was moni-
tored as uricase activity with a radiochemical high pres-
sure liquid chromatography (HPLC) method [6,8], and is
expressed as milliunits/mL plasma (1 Unit = 1 μmol of
urate oxidized per minute at 37°C). Using this assay,
each 8 mg dose of pegloticase contained approximately
145 U of uricase activity. Plasma urate concentration
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The precision for each assay was <5% coefficient of vari-
ation (CV) within the validated ranges, and the lower
limits of quantification (LLOQ) for pUox and pUA were,
respectively, 0.2 mU/mL and 0.5 mg/dL.
pUA and pUox were measured pre-treatment (Day 0)
and at 23 points during treatment (at two hours and on
days 7, 14 and 21 after each infusion; at 48 hours after
infusions 1 and 5; and at a follow-up visit seven weeks
after infusion 5. The plasma half-life (T½) for pegloticase
was determined using all quantifiable pUox values, and
at least three contiguous values were required. For deter-
mining the area under the concentration curve (AUC)
for pUox and pUA, the LLOQ was used for values that
fell below LLOQ.
The “average pUA during treatment” for each patient
was the mean of all scheduled pUA measurements
between Day 2 after infusion 1 and Day 21 after infusion
5 (nominally 21 measurements over 103 days). For pa-
tients who did not complete the study, the interval used
was between Day 2 after infusion 1 and the last pUA
measured within three weeks of the final infusion of
pegloticase. The primary goal of treatment was an “aver-
age pUA during treatment”, as defined, of <6 mg/dL.
Patients who had no more than one pUA >6 mg/dL
during the observation interval were termed “persistent
responders (PR)”; those who had two or more pUA
values >6 mg/dL were termed “transient responders (TR)”.
Non-response (NR) was defined as failure to achieve a
pUA <6 mg/dL for any measurement.
Immune response to pegloticase
Screening ELISAs to detect IgG Ab to both pegloticase
and 10 kDa mPEG were scheduled for seven time points:
at baseline, 21 days after each dose of pegloticase, and at
the follow-up visit (nominally, days 0, 21, 42, 63, 84, 105
and 133). For patients who did not complete the trial,
the final sample was obtained at their last visit. Follow-
ing completion of the trial, some additional studies were
performed to confirm epitope specificity and to better
assess pre-existing Ab to PEG (described in Results). Ali-
quots of plasma that had been stored at -80°C were used
for these studies.
Screening ELISAs (manual procedure)
Plasma samples diluted 1:21 in 1% BSA in PBS were tested
by ELISA for IgG Ab to pegloticase and to 10 kDa mPEG
essentially as described [6,8]. Cutoff values were the
mean + 3 sd A405 obtained for a panel of 99 samples
from normal donors: ≥0.178 with pegloticase, and ≥0.197
with 10 kDa mPEG. The positive QC and reference
standard were from previously studied patients in whom
pegloticase had induced high titer IgG Ab reactive with
both pegloticase and 10 kDa mPEG, but not withunmodified uricase [6,8]. Prior to use, positive QC was
run a minimum of 20 times and ranges were calculated;
this QC was then used to assess the quality of subsequent
assays. The screening ELISAs were validated according to
published guidelines for precision, specificity, recovery,
interference, linearity and range, stability and ruggedness.
Intra-assay precision was ≤7.1% CV with pegloticase as
the plate coat, and ≤11.4% CV with 10 kDa mPEG; inter-
assay precision was <9% CV and <12.1% CV, respectively.
Automated ELISA
The manual screening procedure was modified to use a
Tecan Evo 75 liquid handler and an automated plate
washer (Tecan Mannedorf, Switzerland). As in the
screening ELISA, bound human IgG was detected with
goat anti-human IgG conjugated to alkaline phosphat-
ase, using p-nitrophenyl phosphate as the substrate.
However, the reaction was stopped at 20 minutes with
10% NaOH, rather than when the positive standard
reached an A405 of about 1. The automated procedure
had a lower background and was somewhat more sensi-
tive than the manual screening ELISA. During valid-
ation, the cutoff for the automated ELISA was
determined to be A405 ≥ 0.15.
Competition ELISA (automated procedure)
Plasma samples stored at -80°C were thawed and diluted
1:21 into 1% BSA in PBS, alone or containing 200 μg/mL
of either 10 kDa PEG-diol (that is, PEG terminated with
neither a methoxy group nor an activated linker) or un-
modified recombinant porcine uricase. After incubating at
4°C overnight, 0.1 mL aliquots (containing no competitor
or 20 μg of either PEG-diol or uricase) were tested in
duplicate for IgG Ab to pegloticase, using the automated
ELISA procedure. A decrease of >32% in A405 (compared
to no competitor) indicated specificity for the competing
antigen.
Evaluation of clinical response and safety
At clinic visits prior to each infusion and at follow-up,
the following were performed: a count of tenderness and
swelling of 68 joints; the number of flares experienced
by patients or assessed by study personnel were recorded;
patient and physician global assessment were assessed on
a visual activity scale; and functional status was assessed
by Health Assessment Questionnaire (HAQ). Photographs
of hands were obtained at baseline and at the final follow-
up clinic visit.
Statistics
Except as indicated, data are expressed as mean ± SD.
Statistical analyses were performed using JMP software,
version 9.0 (SAS Institute, Cary, NC, USA). Fisher’s exact
test was used to assess the association between two kinds
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ELISAs using different immobilized antigens was assessed
by ANOVA and linear regression. Means for patient
subgroups were compared by ANOVA. P-values of <0.05
were considered to be significant.
Results
Of 42 patients screened, 12 withdrew prior to dosing.
The 30 who entered the trial had severe gout and com-
monly associated co-morbidities (Table 1). Among these
patients, 27 were naïve to pegloticase and 3 had received
pegloticase in previous clinical trials. Two of the latter
patients had received single doses of 1 mg and 12 mg in
phase 1 trials [6,8], and the third had received multiple
infusions (information about dose and number of infu-
sions unavailable) in a phase 2 trial [13]. All three of
these patients had developed antibodies to pegloticase
following their initial exposure, which had occurred one
to three years before re-exposure in the present trial.
Among the 27 pegloticase-naïve patients, 7 were organ
transplant recipients, who were receiving various im-
munosuppressive regimens to prevent graft rejection
(Table 2).
One pegloticase-naïve patient was withdrawn from the
study before completing the first infusion of pegloticase
due to a syncopal reaction. He was classified as a non-
responder (NR, see Methods), and was included in the
analysis of safety, but not of pharmacokinetics (PK) and
pharmacodynamics (PD).
Pharmacokinetics and pharmacodynamics
Data for pUox and pUA are plotted in Figure 1; PK and
PD parameters derived from these data are listed in
Table 3. In overview, pUA normalized rapidly in all 29
treated patients, and remained <6 mg/dL in 17 persistent
responders (PR), of whom 16 (94%) completed the trial.
Hyperuricemia recurred in 12 transient responders (TR),Table 1 Demographics
Gender 8 F, 22 M
Age, years 57 (25 to 93)
Baseline pUA, mg/dL 10.8 ± 1.2 (9.0 to 13.7)
Tophi, chronic gout arthritis 28 (93%)
Wt, kg 95.0 ± 31.2 (44 to 203)
BMI 31.5 ± 7.5 (19 to 56)





Cardiovascular disease 14 (47%)
BMI, body mass index; pUA, plasma urate concentration.of whom 5 (42%) completed the trial. These response
patterns became evident during the first dosing cycle
(Figure 1A, B), but they were not predicted by dif-
ferences in any baseline parameters (Table 1), includ-
ing gender (P = 0.41), age (P = 0.67) or body weight
(P = 0.74).
By 48 hours after infusion 1, mean pUox for all 29
patients had declined by 12.5% from the level at two
hours, and mean pUA had fallen to 1.0 ± 0.6 mg/dL, a
91% decrease from baseline (Figure 1A, B). By Day 7,
pUox had become undetectable and pUA had risen to
almost 6 mg/dL in the three TR with prior exposure to
pegloticase. Over the next two weeks, eight of the nine
pegloticase-naïve TR also lost response. On Day 21,
pUox was measureable in all 17 PR, but in only 3 of 12
TR; mean pUox for the PR and TR was 7.7 ± 3.8 and
1.1 ± 2.1 mU/mL, respectively (P <0.0001). Conversely,
pUA exceeded 6 mg/dL in 11/12 TR vs. 1/17 PR;
mean pUA was 8.3 ± 2.6 for TR and 2.6 ± 1.8 mg/dL
for PR (P <0.0001).
Mean PK and PD data for all five dosing cycles are
plotted in Figure 1C, D. For PR (Figure 1C), the PK pat-
tern in each cycle was consistent, with Cmax, C48h, Cmin
and AUC for pUox increasing in successive cycles to
approach steady state by the fifth cycle. For each param-
eter, the ratio of the value in cycle 5 to that in cycle 1
was 1.2 to 1.4 (Table 3). This accumulation is consistent
with a T1/2 of 13.0 days (mean for all cycles for the 16
PR who received all five doses; T1/2 in cycle 5 was
13.8 days). The AUC for pUA showed a reciprocal
decline in successive cycles, yielding a ratio of cycle
5/cycle 1 of 0.4. The average pUA during treatment
(defined in Methods) for all PR was 1.0 ± 0.4 mg/dL.
At the follow-up visit seven weeks after the last dose,
mean pUA for the 16 PR was 5.7 ± 3.0 mg/dL.
TR continued to lose response to pegloticase beyond
cycle 1, and only 5 of 12 received the last two infusions
(Figure 1, panel D). The average pUA during treatment
for all TR was 7.5 ± 2.6 mg/dL. For the five who com-
pleted the trial, the ratio of AUC in cycle 5 to cycle 1
was 0.2 for pUox, and 2.4 for pUA; at follow-up, mean
pUA was 11.1 ± 1.4 mg/dL.
Immune response to pegloticase
Figure 2A, B plots the baseline and the highest A405
values attained during treatment in screening ELISAs for
Ab to pegloticase and 10 kDa mPEG. Prior to treatment
(blue symbols), most patients were negative or border-
line positive in both screens. Of note, the single NR had
the highest pre-treatment response to both antigens.
During treatment (red symbols), 3 of 17 PR developed
positive screens on six occasions (5.2% of 115 samples
tested). A405 in the anti-pegloticase screen exceeded 0.4
on only one occasion in one patient. By contrast, all 12
Table 2 Organ transplant recipients: immunosuppressive therapy
Patient ID (age) Organs transplanted Immunosuppressive regimen Year initiated
203 (65 y) kidney Mycophenolate mofetil 500 mg QD 1995
207 (45 y) kidney Cyclosporine 175 mg BID; Azathioprine 100 mg QD 1994
208 (32 y) kidney + pancreas Mycophenolate mofetil 500 mg BID; Tacrolimus 2 mg BID 2000
211 (47 y) kidney + pancreas Cyclosporine 150 mg BID; Azathioprine 50 mg QD 1991
214 (55 y) kidney Cyclosporine 125 mg TID 1991
233 (41 y) kidney x 2 Cyclosporine 75 mg BID; Azathioprine 50 mg QD 1993*
238 (51 y) kidney Cyclosporine 50 mg BID; Mycophenolate mofetil 1000 mg BID 1999
*Year of second kidney transplant. The regimen taken between 1988 (year of first kidney transplant) and 1993 was not recorded.
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ples tested were positive, and the mean of the highest
A405 values in both ELISAs was 20-fold higher than the
mean for Day 0 (P <0.0001). In other studies, IgG anti-
pegloticase Ab titers in TR ranged from approximately
1:100 to >1:12,000, and, as observed during phase I test-
ing, the predominant IgG subclasses were IgG2 and IgG3
[6,8]. In mixing experiments, Ab-positive plasma samples
did not appreciably inhibit pegloticase enzymatic activity
(that is, Ab were not neutralizing).Figure 1 Pharmacokinetics and pharmacodynamics of pegloticase inf
pegloticase dosing cycle on all 29 patients. (A) Plasma uricase activity (pUo
is shown as a reference. (B) Plasma uric acid concentration (pUA). The dash
with a persistent response to pegloticase (PR); red = patients with a transie
who had received pegloticase >1 year prior to the present trial. P-values sh
Mean pUox and pUA during all five dosing cycles for PR (C) and TR (D). Sy
under treatment in each cycle. Error bars, standard deviation.As noted, all TR developed Ab to both pegloticase and
10 kDa mPEG. That the same Ab recognizes both anti-
gens is suggested by the strong correlation between
A405 values in the two ELISAs (Figure 2C), and between
A405 values obtained in ELISAs using pegloticase and
PEG-ADA as plate coatings (Figure 2D). PEG is the only
common feature of these two entities: in PEG-ADA,
5 kDa mPEG is linked to bovine ADA via a succinyl
ester, whereas in pegloticase, 10 kDa mPEG is attached
to porcine uricase by a one carbon urethane bond.used at three-week intervals. Panels A and B: Data for the first
x), plotted on a logarithmic scale (y-axis). The dashed line at 1 mU/mL
ed line at 6 mg/dL is shown as a reference. Symbols: blue = patients
nt response to pegloticase (TR); open red triangles = 3 non-naïve TR,
own are for comparison of the means for PR and TR. Panels C and D:
mbols: blue circles = pUox; red squares = pUA; n = number of patients
Table 3 Summary of pharmacokinetic parameters
Patients All PR TR P, PR vs. TR
Infusion #1
Cmax (t = 2 h) mU/mL 25.6 ± 5.0 26.2 ± 5.9 24.7 ± 3.4 0.45 (ns)
C48h (t = 48 h) mU/mL 22.4 ± 5.6 22.9 ± 6.3 21.7 ± 4.7 0.60 (ns)
Cmin (t = 21 days) mU/mL 4.9 ± 4.6 7.7 ± 3.8 1.0 ± 2.2 <0.0001*
T1/2, days 11.4 ± 3.7
a 12.3 ± 3.7 9.7 ± 3.3a 0.08 (ns)
AUC2 h-21 days, mU*mL
−1*d 277 ± 112 328 ± 100 204 ± 85 0.0016*
Infusion #5
Cmax (t = 2 h) mU/mL 31.4 ± 9 10.5 ± 12 <0.0005*
C48h (t = 48 h) mU/mL 29.9 ± 9.7 4.9 ± 7.3 <0.0001*
Cmin (t = 21 days) mU/mL 10.6 ± 5.1 0.2 <0.0003*
T1/2, days 13.8 ± 3.0 -
b
AUC2 h-21 days, mU*mL
−1*d 422 44
AUC, inf #5/inf #1 1.3 0.2
Average for all infusions
Cmax (t = 2 h) mU/mL 30.9 ± 2.9 16.9 ± 5.4 0.0009*
Cmin (t = 21 days) mU/mL 9.9 ± 1.4 0.4 ± 0.4 <0.0001*
T1/2, days 13.0 ± 3.4 -
b
AUC2 h-21 days, mU*mL
−1*d 397 ± 38 105 ± 65 <0.0001*
aT1/2 could not be calculated for three non-naive patients; therefore N = 26 (all), 17 (PR), 9 (PR);
bT1/2 could not be calculated. AUC, area under the concentration
curve.
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gens, we performed a competition ELISA to interrogate
Ab binding to antigens in solution (Figure 2E, F). Spiking
Ab-positive plasma samples with 10 kDa PEG-diol (which
lacks a methoxy group), but not with un-PEGylated uri-
case, caused significant inhibition of the anti-pegloticase
ELISA. Inhibition by PEG, but not uricase, was observed
with pre-treatment samples from 8 patients (Figure 2E),
and with post-treatment samples from all 13 Ab-positive
patients (Figure 2F). Considering all results in Figure 2, we
conclude that Ab to pegloticase are directed at internal
ethylene oxide units of PEG, rather than to the uricase
protein, the methoxy terminus of mPEG, or the protein-
polymer junction.
The evolution of Ab to pegloticase varied among
patients, presumably due to factors that can influence
the timing of induction of immunity (for example, prior
exposure to antigen), and the sensitivity of Ab detection
(for example, the avidity of Ab for circulating antigen).
Figure 3 illustrates patterns for three patients. In patient
204 (Figure 3A), who had received pegloticase two years
earlier, IgG Ab increased sharply between days 2 and 7
after re-exposure, coincident with elimination of pUox
(he received no further treatment). The other two patients
were naïve to pegloticase and received all five infusions. In
patient 229 (Figure 3B), IgG and IgM Ab to pegloticase
were present in pre-treatment plasma. Both isotypes de-
creased after the first dose of pegloticase, then recoveredduring dosing cycles 2 and 3, and rose further as pUox
declined in cycles 4 and 5. In patient 218 (panel 3C), IgM
Ab to pegloticase appeared two weeks after infusion 1,
preceding IgG Ab by four weeks. Both isotypes rose more
rapidly after pUox became un-measureable in cycle 3.
pUA levels in each of these three patients mirrored the
fluctuation in circulating pUox (Figure 3D).
Of interest, among the 27 pegloticase-naïve patients,
only 1 of 7 (14%) organ transplant recipients developed
Ab to pegloticase or 10 kDa mPEG, vs. 9 of 20 (45%)
non-recipients. One of the six Ab-negative transplant
recipients received only two doses of pegloticase, but at
the point she was last tested for Ab (Day 42), all nine
non-recipients had already developed Ab.
Safety and tolerability
As in previous trials of pegloticase, the most common
adverse events were gout attacks, experienced by 27/30
patients (90%), and infusion reactions, which occurred
in 13/30 patients (43%). Among Ab-positive patients, 8
of 13 (62%) experienced reactions during 10 of 41 (24%)
infusions; 5 withdrew from the trial because of these
reactions, which are summarized in Table 4. Among Ab-
negative patients, only 5 of 17 (29%) had reactions associ-
ated with 11 of 82 (13%) infusions. These reactions were
treated by slowing or stopping the infusion of pegloticase
and administering diphenhydramine; when the reaction
resolved, infusion of pegloticase was resumed at a slower
Figure 2 Antibody response to pegloticase. Screening ELISAs for Ab to pegloticase (A) and10 kDa mPEG (B). Horizontal axis: N = non,
P = persistent, T = transient responder. Symbols: blue = pre-treatment; red = highest A405 during the trial; triangles = the non-responder. (C)
Correlation between the anti-pegloticase and anti-10 kDa mPEG ELISAs. The highest A405 values during treatment from 2A and B are re-plotted.
Symbols: blue = persistent (P), red = transient (T), green = non-responder (N). (D) Correlation between ELISAs for Ab to pegloticase and PEGylated
adenosine deaminase (PEG-ADA). Conditions for the ELISAs were the same except for the plate coating. Two samples, obtained on Day 0 (open
symbols) and at the final visit (filled symbols) from six patients (distinguished by symbol shape) were studied. Competition ELISA (see Methods).
(E). Pre-treatment. The non-responder (blue underline) and three previously treated patients (blue asterisks) are indicated on the horizontal axis.
(F). Post-treatment. The last sample obtained from each Ab-positive patient was tested to minimize competition from circulating pegloticase
(pUox was undetectable or <0.3 mU/mL). Data plotted are the mean and SEM for the 13 samples tested.
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treatment.
As a strategy for minimizing infusion reactions in
patients receiving 8 mg of pegloticase every two weeks, it
has been recommended that if pUA measured prior to
infusions exceeds 6 mg/dL on two consecutive occasions,
discontinuation of treatment should be considered [4,5].
This strategy is also reliable in marking the development
of anti-PEG Ab and loss of efficacy in patients receiving
the same dose every three weeks. Thus, as shown in Fig-
ure 4A, among all PR, trough (pre-infusion) pUA was
>6 mg/dL on only single occasions in 2 of 17 patients
(7.7 mg/dL after infusion 1 in one case, and 6.1 mg/dL
after infusion 2 in the other). By contrast all trough/pre-
infusion pUA values were >6 mg/dL in 11 of 12 TR, and
after infusions 3 to 5 in the 12th patient (Figure 4B).
Four patients experienced serious adverse effects
(SAEs). There was no discernible common mechanism,and no relationship to infusions of pegloticase. A patient
with diabetes mellitus type 2 required hospitalization for
hyperglycemia, and a patient receiving warfarin was hos-
pitalized for a gastrointestinal bleed; both went on to
complete treatment and were PR. The other two SAEs
occurred in organ transplant recipients. A 32-year-old
female with type 1 diabetes mellitus, who was one of
two kidney/pancreas recipients, had a duodenal perfor-
ation during her second dosing cycle, which led to loss
of her pancreas graft and withdrawal from the trial. She
was negative for anti-PEG Ab and had a pUA of 0.9 mg/dL
at three weeks after her last dose of pegloticase. A 41-year-
old man who had twice received renal transplants for
Alport’s hereditary nephritis, had a fatal myocardial infarc-
tion nine days after his third dose of pegloticase. He had
known coronary artery disease and other cardiac risk
factors (hypertension, renal insufficiency, obesity, obstruc-
tive sleep apnea). Anti-PEG Ab developed after one dose
Figure 3 Evolution of Ab to pegloticase and relation to pUox and pUA in three patients with a transient response to treatment with
pegloticase. (A-C) Change during treatment in pUox (left vertical axis) and in the ELISAs for Ab to pegloticase (right vertical axis). (D) Change
during treatment in pUA for the same three patients.
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8.3 mg/dL; his pUA at a scheduled clinic visit two days
before the fatal event was 11.6 mg/dL.
Because the current trial was short-term and open
label, the ability to assess benefit was limited. However,
for the 21 patients who completed the trial, five measures
of clinical response showed improvement when observa-
tions at week 19 (seven weeks after the final infusion)
were compared with baseline (Table 5). For four of the
five parameters, the median percentage improvement in
PR exceeded that for TR by 1.6- to 7.2-fold (tender joint
count, patient pain, and both physician and patient globalTable 4 Infusion reactions leading to withdrawal from study
Patient ID (age) Number infusions Reactions
210 (50 y) 2 Nausea, dyspnea, hypoxemia, tachyc
diaphoresis, hypotension, systemic ra
213 (43 y) 3 Chills, nausea, chest tightness, system
219 (67 y) <1 Syncope
237 (25 y) 3 Chest tightness, dyspnea, flushing, ta
241 (70 y) 2 Pruritus, chest tightness, hypotension
hypoxemiaassessment). The sustained reduction in pUA to <2 mg/dL
in PR was in some cases accompanied by reduction in size
or complete resolution of digital tophi, as illustrated in
Figure 5. Resolution of tophi in another PR patient was re-
ported elsewhere, in an analysis of oxidative stress status
in patients in this clinical trial [7].
Discussion
Efficacy of every three-week dosing
Infusing 8 mg of pegloticase every three weeks con-
trolled hyperuricemia in 17 of 30 patients. In the 16 PR
who received five doses, pUA averaged approximatelyTreatment/outcome
ardia,
sh
IV fluids, O2, epinephrine, diphenhydramine;
hospitalized overnight. All symptoms resolved.
ic urticaria Infusion slowed, acetaminophen, diphenhydramine.
All symptoms resolved.
Infusion stopped. All symptoms resolved.
chycardia Infusion stopped; diphenhydramine. All symptoms resolved.
, Infusion stopped; IV fluids, O2, diphenhydramine.
All symptoms resolved.
Figure 4 Pre-infusion (trough) pUA as a marker for a significant
antibody response to pegloticase. All pUA determinations
obtained immediately prior to each infusion of pegloticase
(nominally 21 days after the preceding infusion) are plotted. The
dashed line at 6 mg/dL is shown as a reference. (A) Persistent
responders (blue symbols). The open circles and open triangles
represent data for the two PR who had single pre-infusion (trough)
pUA values >6.0 mg/dL. (B) Transient responders (red symbols). The
asterisks represent data for the single TR in whom any pre-infusion
(trough) pUA <6 mg/dL was observed.
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http://arthritis-research.com/content/16/2/R631 mg/dL, a decrease of >90% from baseline, during the
15-week treatment period. This is comparable to pUA
achieved over the same period in patients classified as
“responders” in phase 3 testing, who received 8 mg of
pegloticase every two weeks [4].
Two points regarding PK and PD data in persistent
responders are noteworthy. Control of pUA in PR was
unrelated to body weight (44 to 203 kg), and Cmax,
Cmin and AUC for pUox were approximately 30%
higher during the fifth dosing cycle than during the first.
This “positive accumulation” reflects the 13-day half-life
of pegloticase, and is consistent with PK modeling [14].







Tender joint count 13 2 7
Swollen joint count 9 6 4
Patient global assessment 44.0 9.0 6
Patient pain 52.0 23.0 6
Physician global assessment 45.5 24.5 6maintained, indicate that plasma uricase activity pro-
vided by 8 mg of pegloticase must approach or exceed
uric acid production over a three-week dosing interval
(for further discussion, see [7]). A very low pUA mobi-
lizes urate from tophi, and maintaining uricase in plasma
throughout the dosing cycle ensures its degradation.
This is important in refractory gout patients, in whom
urate excretion is often impaired.
Given the short trial period and patient population, it
was gratifying to observe meaningful improvement in
pain, tender joint count and global assessment of disease
activity, as well as resolution or reduction in tophus size
in some patients. Almost all patients experienced gout
flares, but this was expected given the indication for
treatment, and because the frequency of flares tends to
increase with initiation of all urate-reducing therapies.
Maintaining a very low pUA with continued treatment
would be expected to progressively reduce both gout
flares and tophus size [15].
Anti-PEG Ab response
None of the 17 PR mounted a significant or sustained Ab
response to pegloticase. In the other 13 of 30 patients
(43%), Ab to pegloticase was associated with a rapid de-
cline in pUox and increase in pUA. These events occurred
between days 2 and 7 after the first infusion in the three
patients with a prior exposure to pegloticase, and over the
next two weeks in eight of nine pegloticase-naïve TR. Ab
to pegloticase doubled the risk of infusion reactions; 5 of
13 Ab-positive patients withdrew from the trial due to
these reactions, vs. 0 of 17 Ab-negative patients.
Similar to the present results, during phase 1 testing,
single doses of pegloticase (0.5 to 12 mg) induced IgG
and IgM anti-pegloticase Ab within three weeks in 38%
of patients [6,8]. In previous phase 2 and 3 trials lasting
up to six months, Ab to pegloticase was detected (using
different methods) at some point in >80% of patients;
the highest titers were preferentially associated with loss
of efficacy and infusion reactions [4,13].
Epitope specificity was not addressed in reports of pre-
vious phase 2 and 3 trials. Our present findings add to
evidence obtained during phase 1 testing by demonstrat-
ing that Ab to pegloticase recognize the ethylene oxide
backbone of PEG, rather than the uricase protein, theedian improvement persistent
esponders (n = 16)
Median improvement transient/






Figure 5 Resolution of digital tophi in a persistent responder.
(A). Prior to treatment with five doses of pegloticase, 8 mg, infused
at three-week intervals. (B). At follow-up visit.
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of mPEG. Our findings do not support speculation that
Ab with high affinity for methoxy groups contribute to
the loss of efficacy of pegloticase [16]. With longer treat-
ment, some patients might develop Ab to the uricase pro-
tein. However, the initial Ab formed, which are responsible
for rapid clearance of pegloticase and loss of efficacy, are
directed at PEG.
It is noteworthy that anti-PEG Ab were detected in
pre-treatment plasma from eight patients. Three of these
patients had previously received pegloticase, but five had
not; they represented 19% of the 27 pegloticase-naïve
patients, and half of the 10 non- or transient responders.
Pre-existing anti-PEG Ab may have resulted from expos-
ure to “free” (that is, unconjugated to protein) PEG-diols,
or various ether and fatty acid derivatives of PEG, which
have been used for decades as solubilizers, stabilizers or
excipients in cosmetics, laxatives and medicinal prepara-
tions. The general prevalence of anti-PEG Ab, and factors
that may be responsible for their development, is a subject
we are pursuing.
A recent “critical review” citing flawed or un-validated
methods has questioned the induction of anti-PEG Ab by
PEGylated therapeutic agents in humans, and has argued
that biological effects attributed to anti-PEG Ab “lack the
characteristics of a bona fide Ab reaction” [11]. Our pre-
sent findings, obtained with validated methods, unequi-
vocally demonstrate that anti-PEG Ab are relevant to
pegloticase therapy. The temporal relationship between
exposure to the PEGylated antigen and anti-PEG Ab
induction, including an accelerated response upon re-
exposure to pegloticase, are entirely consistent with a
“bona fide Ab reaction”. Much remains to be learned
about how the immune system recognizes and responds
to PEG, which has physical and chemical properties very
different from protein and other polymeric antigens.Treatment of organ transplant recipients with pegloticase
Managing gout in organ transplant recipients is com-
plicated by serious underlying diseases, and by drug regi-
mens needed to treat these conditions and to prevent graft
rejection [12]. We felt that these patients could benefit
from the ability of pegloticase to rapidly deplete urate de-
posits, even when urate excretion is impaired, while their
chronic immunosuppression might dampen the immune
response to pegloticase. Five of 7 transplant recipients did
respond well to pegloticase, and only 1 of 7 developed Ab
to pegloticase, vs. 9 of 20 pegloticase-naïve non-transplant
recipients. Although the number of patients is small, this
difference supports the investigation of immunosuppres-
sive strategies as an adjunct to pegloticase therapy.
The burden of chronic disease carried by organ trans-
plant recipients is underscored by SAEs in two patients,
especially a fatal myocardial infarction in a 41-year-old
renal transplant recipient with hereditary nephritis. Anti-
PEG Ab had developed rapidly in this patient, and he was
markedly hyperuricemic during the month prior to his
myocardial infarction. In addition to his multiple other
cardiac risk factors, gout and hyperuricemia independently
predict mortality in patients with cardiovascular disease
[17-21]. The risk may be greatest in patients with chronic
tophaceous gout and a high level of hyperuricemia [22].
Conclusions
Infusing 8 mg of pegloticase every three weeks is con-
sistent with PK and effectively controlled hyperuricemia
in 17 of 30 study patients, and five such infusions led to
the amelioration of symptoms due to gout. Whether or
not every three-week dosing is used routinely, physicians
and patients may be reassured by our findings that miss-
ing an occasional every two-week dose of pegloticase
will not result in loss of control. In patients who have
had a good response to an every two-week schedule,
switching to every three-week dosing may be an option,
particularly for patients who are frail or must travel a
distance to an infusion facility. In 13 of 30 patients, Ab
to pegloticase that recognize PEG rather than the uricase
protein caused the rapid elimination of pegloticase from
plasma, associated with loss of efficacy and a doubled
risk of infusion reactions. Anti-PEG Ab usually appeared
after the first dose of pegloticase, and were pre-exisiting
in 5 of 10 non- or transient responders who were naïve
to pegloticase. Two consecutive trough (pre-infusion)
pUA values >6 mg/dL were reliable markers for anti-
PEG Ab and loss of efficacy. Pegloticase can be effective,
and may be less immunogenic in organ transplant recipi-
ents with refractory gout; the risks and benefits in these
complex patients should be carefully considered. Our find-
ings suggest that an immunosuppressive strategy should be
investigated as a means of reducing the antibody response
to pegloticase.
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